Terms: = Prostate cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Prognosis
2002 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
3. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
4. Dishevelled Segment Polarity Protein 3 (DVL3) Induced by Bacterial LPS Promotes the Proliferation and Migration of prostate cancer Cells through the TLR4 Pathway.
Zhang Y; Lin N; Liu X; Yao T
Arch Esp Urol; 2024 Mar; 77(2):193-201. PubMed ID: 38583012
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
6. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
7. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL; Sutherland SI; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG
Prostate; 2024 Jun; 84(8):747-755. PubMed ID: 38544345
[TBL] [Abstract] [Full Text] [Related]
8. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
9. CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
Dwina Y; Zaid LSM; Saraswati M; Rachmadi L; Kekalih A; Rahadiani N; Louisa M; Agustina H; Mochtar CA; Hamid ARAH
Prostate; 2024 Jun; 84(8):738-746. PubMed ID: 38528654
[TBL] [Abstract] [Full Text] [Related]
10. A Novel DNA Aptamer Probe Recognizing Castration Resistant prostate cancer in vitro and in vivo Based on Cell-SELEX.
Zhong J; Liu D; Yang Q; Ding J; Chen X
Drug Des Devel Ther; 2024; 18():859-870. PubMed ID: 38524880
[TBL] [Abstract] [Full Text] [Related]
11. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Patients With prostate cancer: A Systematic Review and Meta-Analysis.
Xiang Q; Liu Y; Xiao J; Ou L; Du J
Am J Mens Health; 2024; 18(2):15579883241234747. PubMed ID: 38514969
[TBL] [Abstract] [Full Text] [Related]
13. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
14. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
15. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
16. Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and prostate cancer.
Mizutani K; Sugiyama S; Kameyama K; Kamei S; Yokoi S; Morikawa A; Takeuchi M; Seike K; Yamada T; Ehara H; Sawada S; Hirade K; Furuta H; Matsunaga K; Yamada T; Sakamoto I; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2024; 21(2):203-212. PubMed ID: 38423595
[TBL] [Abstract] [Full Text] [Related]
17. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
[TBL] [Abstract] [Full Text] [Related]
18. Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.
Rao S; Verrill C; Cerundolo L; Alham NK; Kaya Z; O'Hanlon M; Hayes A; Lambert A; James M; Tullis IDC; Niederer J; Lovell S; Omer A; Lopez F; Leslie T; Buffa F; Bryant RJ; Lamb AD; Vojnovic B; Wedge DC; Mills IG; Woodcock DJ; Tomlinson I; Hamdy FC
Genome Med; 2024 Feb; 16(1):35. PubMed ID: 38374116
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic Value of the Modeled prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant prostate cancer Treated With Taxanes in FIRSTANA.
Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
[TBL] [Abstract] [Full Text] [Related]
20. [Functional outcomes of robot-assisted radical prostatectomy with preservation of pelvic stabilized structure and early elevated retrograde liberation of neurovascular bundle].
Liao XY; Bao YG; Liu ZH; Yang L; Qiu S; Liu LR; Han P; Wei Q
Zhonghua Wai Ke Za Zhi; 2024 Feb; 62(2):128-134. PubMed ID: 38310380
[No Abstract] [Full Text] [Related]
[Next]
